Sarkar S, Rajaratnam S, Chacko G, Chacko AG (2014) Endocrinological outcomes following endoscopic and microscopic transsphenoidal surgery in 113 patients with acromegaly. Clin Neurol Neurosurg 126:190–195

Article  PubMed  Google Scholar 

Nomikos P, Buchfelder M, Fahlbusch R (2005) The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical ‘cure’. Eur J Endocrinol 152(3):379–387

Article  CAS  PubMed  Google Scholar 

Fleseriu M, Biller BMK, Freda PU, Gadelha MR, Giustina A, Katznelson L et al (2021) A pituitary society update to acromegaly management guidelines. Pituitary 24(1):1–13

Article  PubMed  Google Scholar 

Donegan DM, Iñiguez-Ariza N, Sharma A, Nippoldt T, Young W, Van Gompel J et al (2018) Necessity of multimodal treatment of acromegaly and outcomes. Endocr Pract 24(7):668–676

Article  PubMed  Google Scholar 

Melmed S, Bronstein MD, Chanson P, Klibanski A, Casanueva FF, Wass JAH et al (2018) A consensus statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol 14(9):552–561

Article  PubMed  PubMed Central  Google Scholar 

Urwyler SA, Samperi I, Lithgow K, Mavilakandy A, Matheou M, Bradley K et al (2024) Efficacy of Cabergoline in non-irradiated patients with acromegaly: a multi-centre cohort study. Eur J Endocrinol. 2024;190(1):113–20

Venegas-Moreno E, Vazquez-Borrego MC, Dios E, Gros-Herguido N, Flores-Martinez A, Rivero-Cortés E et al (2018) Association between dopamine and somatostatin receptor expression and Pharmacological response to somatostatin analogues in acromegaly. J Cell Mol Med 22(3):1640–1649

Article  CAS  PubMed  Google Scholar 

Ferone D, de Herder WW, Pivonello R, Kros JM, van Koetsveld PM, de Jong T et al (2008) Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. J Clin Endocrinol Metab 93(4):1412–1417

Article  CAS  PubMed  Google Scholar 

Katznelson L, Laws ER, Melmed S, Molitch ME, Murad MH, Utz A et al (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933–3951

Article  CAS  PubMed  Google Scholar 

Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF et al (2010) A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metabolism 95(7):3141–3148

Article  CAS  Google Scholar 

Giustina A, Biermasz N, Casanueva FF, Fleseriu M, Mortini P, Strasburger C et al (2024) Consensus on criteria for acromegaly diagnosis and remission. Pituitary 27(1):7–22

Article  CAS  PubMed  Google Scholar 

Gomez-hernandez K, Ezzat S, Asa SL, Mete O (2015) Clinical implications of accurate subtyping of pituitary adenomas: perspectives from the treating physician. TJPATH. [cited 2023 Aug 18]; Available from: http://www.turkjpath.org/doi.php?doi=10.5146/tjpath.2015.01311

Ferone D, van Hagen MP, Kwekkeboom DJ, van Koetsveld PM, Mooy DM, Lichtenauer-Kaligis E et al (2000) Somatostatin receptor subtypes in human thymoma and Inhibition of cell proliferation by octreotide in vitro. J Clin Endocrinol Metabolism 85(4):1719–1726

Article  CAS  Google Scholar 

Pivonello R, Ferone D, de Herder WW, Kros JM, Del Caro B, Arvigo ML (2004) Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metabolism 89(5):2452–2462

Article  CAS  Google Scholar 

Volante M, Brizzi MP, Faggiano A, La Rosa S, Rapa I, Ferrero A et al (2007) Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol 20(11):1172–1182

Article  CAS  PubMed  Google Scholar 

Gatto F, Feelders RA, van der Pas R, Kros JM, Waaijers M, Sprij-Mooij D et al (2013) Immunoreactivity score using an Anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly. J Clin Endocrinol Metabolism 98(1):E66–71

Article  CAS  Google Scholar 

Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25(4):402–408

Article  CAS  PubMed  Google Scholar 

Goyal-Honavar A, Sarkar S, Asha HS, Kapoor N, Thomas R, Balakrishnan R et al (2021) Impact of experience on outcomes after endoscopic transsphenoidal surgery for acromegaly. World Neurosurg 151:e1007–e1015

Article  PubMed  Google Scholar 

Rass L, Rahvar AH, Matschke J, Saeger W, Renné T, Aberle J et al (2022) Differences in somatostatin receptor subtype expression in patients with acromegaly: new directions for targeted therapy? Hormones 21(1):79–89

Article  PubMed  Google Scholar 

Kiseljak-Vassiliades K, Xu M, Mills TS, Smith EE, Silveira LJ, Lillehei KO et al (2015) Differential somatostatin receptor (SSTR) 1–5 expression and downstream effectors in histologic subtypes of growth hormone pituitary tumors. Mol Cell Endocrinol 417:73–83

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sandret L, Maison P, Chanson P (2011) Place of Cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab 96(5):1327–1335

Article  CAS  PubMed  Google Scholar 

Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens JL et al (1998) Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 83(2):374–378

Article  CAS  PubMed  Google Scholar 

Iacovazzo D, Carlsen E, Lugli F, Chiloiro S, Piacentini S, Bianchi A et al (2015) Factors predicting Pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. Eur J Endocrinol/Eur Fed Endocr Soc. 174